Phase 2 Randomized, Dose-Ranging Study of Oxymetazoline Cream for Treatment of Persistent Facial Erythema Associated With Rosacea.

CONCLUSION: Oxymetazoline 1.0% QD provided the optimal dosing regimen and was selected for evaluation in phase 3 clinical studies. J Drugs Dermatol. 2018;17(3):308-316. PMID: 29537449 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/29537449?dopt=Abstract

Source: Journal of Drugs in Dermatology - March 17, 2018 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

More News: Dermatology | Rosacea | Skin | Study